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ABSTRACT p66shc is a gene that regulates the level of reactive oxygen species (ROS), apoptosis induction, and 
lifespan in mammals. Mice knocked out for p66shc have a lifespan ~30% longer and demonstrate an enhanced 
resistance to oxidative stress and age-related pathologies such as hypercholesterolemia, ischemia, and hypergly-
cemia. In this respect, p66shc is a promising pharmacological target for the treatment of age-related diseases. In 
this review, an attempt has been made to survey and put to a critical analysis data concerning the involvement 
of p66shс in the different signaling pathways that regulate oxidative stress and apoptosis.
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ABBREVIATIONS Akt – protein kinase B, Cdc42 (cell division control protein 42 homolog) – a small GTPase of the 
Rho-subfamily, Cyt C – cytochrome c, DMTU – dimethylthiourea,  Grb2 – growth factor receptor-bound protein 
2, ERK – extracellular signal-regulated kinases, HIV-1 – human immunodeficiency virus 1, IMS – intermem-
brane space of mitochondria, JNK – c-Jun N-terminal kinases, MAPK – mitogen-activated protein kinases, 
mHSP70 – mitochondrial 70 kilodalton heat shock proteins, MnSOD – mitochondrial superoxide dismutase, 
PKCβ – protein kinase Cβ, Pin-1 – peptidyl-prolyl cis/trans isomerase, PP2A – Protein phosphatase 2, Prx1 – 
peroxiredoxin 1, PTP – permeability transition pore, PTP-PEST – protein tyrosine phosphatase that contains a 
C-terminal PEST motif, Rac-1 – ras-related C3 botulinum toxin substrate 1, RAS – rat sarcoma viral oncogene, 
REF-1 – redox factor 1, ROS – reactive oxygen species, SOS1 (Son of Sevenless) – guanine nucleotide-binding 
protein, TIM – translocase of the inner membrane of mitochondria, TMPD – N,N,N’,N’- tetramethyl-p-phenyl-
diamine, TOM – translocase of the outer membrane of mitochondria. 
INTRODUCTION
The identification of the mutations that lead to the 
prolongation of the lifespan of various model organ-
isms shows that aging can be considered as a genetic 
program [1]. One of these genes is p66shc, the deletion 
of which results in a 30% increase in the lifespan. It is 
important to note that mice knocked out for p66shc, in 
comparison with other mouse models with a prolonged 
lifespan (e.g., mice with the deleted gene of a growth 
hormone receptor), are fertile and exhibit a normal 
phenotype [2]. These mice are resistant to oxidative 
stress and age-related pathologies such as atheroscle-
rosis [3], endothelial disorders [4], AGE (advanced gly-
cation end products)-dependent glomerulopathy re-
lated to diabetes mellitus [5, 6], and ethanol-induced 
liver affection [7].
P66shc is an adaptor protein which is coded for by 
a single locus in Drosophila (dShc), and by four loci in 
mammals – Shc (ShcA), Sli (ShcB), Rai (ShcC) [8], and 
RalP [9]. The four mammalian loci code for at least 7 
proteins due to the usage of alternative start codons 
and alternative splicing. Three isoforms encoded by the 
ShcA locus are designated according to their molecular 
weights as p46shc, p52shc, and p66shc, respectively. 
These proteins participate in the regulation of prolif-
eration (p46shc and p52shc) and apoptosis (p66shc) [8].
P66shc is considered to be a relatively “young” pro-
tein since it is not found in yeast ( Saccharomyces), 
nematodes (Caenorhabditis), and insects (Drosophila) 
but appears in amphibians (Xenopus), fishes (Fugu 
rubripes), and mammals [8]. Since it is the longest iso-
form, p66shc contains all the most ancient domains that 
are found in short isoforms p46shc and p52shc (Fig.1), 
including: the N-terminal phosphotyrosine-binding 
domain (PTB), the middle collagen homology domain 
(CH1), and the C-terminal Src-homology domain (SH2). 
The isoforms that are longer than p46shc contain some 
additional N-terminal domains: the cytochrome c bind-
ing domain (CB), which is common to both p52shc and 
p66shc, and the collagen-homology domain (CH2), 
which is unique to p66.
P46shc and p52shc fulfill the function of adaptor 
proteins transmitting signals from various tyrosine-ki-
nase receptors, which phosphorylate tyrosine residues 
in these proteins. Phosphorylation of p46shc/p52shc 
induces the formation of a complex between GRb2 
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(adaptor protein) and SOS (nucleotide exchange fac-
tor), which leads to RAS activation and the induction of 
the mitogene-activated protein kinases (MAPK) path-
way. Although p66shc as p46shc/p52shc is phosphor-
ylated by tyrosine-kinase receptors and interact with 
the GRb2/SOS complex, it, apparently, does not acti-
vate MAPK [10]. The competition between p66shc and 
p52shc for binding with GRb2 [11] and p66shc-induced 
displacement of SOS from its complex with GRb2 [12, 
13] can mediate the regulation of signal transduction 
from receptors. However, experiments on animal mod-
els knocked out for p66shc showed that the role of this 
protein in lifespan regulation, oxidative stress, and ap-
optosis is accounted for by the CH2 and CB domains, 
which are not essential for the primary adaptor func-
tion of the protein. 
P66, OXIDATIVE STRESS, AND APOPTOSIS.
Studies on mice with a knocked out p66shc gene re-
vealed decreased levels of intracellular ROS, as deter-
mined by means of ROS-sensitive probes, as well as 
reduced levels of oxidative damages to DNA and pro-
teins, estimated by measuring 8-oxo-deoxiguanosine 
and nitrotyrosines [3,4,14-16]. The mutant mice ex-
hibited higher resistance to paraquat-induced oxida-
tive stress [2]. Studies on various p66shc-deficient cell 
lines  (ones with a deleted p66shc-gene, or cells with a 
dominant-negative phenotype caused by a Ser36Ala 
substitution in the target gene) derived from mice, rats, 
and a human showed that p66shc plays an important 
role in apoptosis induced by various agents (Table 1). 
P66shc-mediated oxidative stress is assumed to be the 
key factor in these experimental models of apoptosis. 
In particular, certain published data indicate the im-
portance of p66shc-induced oxidative stress in the p53-
dependent apoptotic pathway [14]. Data derived from 
physiological experiments have led to similar conclu-
sions (Table 2). 
Posttranslational modifications have been shown 
to play an important role in the pro-apoptotic activity 
of p66shc. For instance, phosphorylation at Ser36 lo-
cated in the CH2-domain is indispensable in hydrogen 
peroxide- or UV-induced apoptosis [2]. Phosphoryla-
tion itself is carried out by such kinases as JNK (in re-
sponse to UV or amyloid β-peptide) [23, 33], ERK [34], 
and PKCβ in response to treatment by H2O2 [35]. Phos-
phorylation at Ser36 promotes interaction with 14-3-
3 proteins [36], tyrosine phosphatase PTP-PEST [37], 
and prolylisomerase Pin-1 [35]. While the significance 
of the first two interactions remains unclear, Pin-1-
mediated p66shc isomerization plays a crucial role in 
the regulation of p66shc transport into mitochondria 
and activation of mitochondrion-dependent apoptosis 
(see below).
However, despite the great amount of research con-
firming the pro-apoptotic functions of p66shc, some 
studies suggest that it can also exhibit antiapoptotic 
effects. In a human breast cancer model, as well as in 
a human stem cell model, it was shown that the sup-
pression of p66shc expression protects from hypoxia-
induced cytotoxicity. It was also found that low oxy-
gen concentrations lead to p66shc activation, which, in 
turn, induces expression of the Notch-3 gene. The latter 
accounts for the self-renewal of stem cells and their 
survival under hypoxia. Notch-3 induces the expres-
sion of carboanhydrase IX, which also accounts for a 
hypoxia resistant phenotype [38]. Therefore, a connec-
tion exists between p66shc and the pathway that un-
derlies the protection of stem cells from hypoxia. These 
data clarify the role of p66shc in homeostasis and the 
self-renewal of stem cells, which are known to occupy 
specialized tissue compartments or niches containing 
small amounts of blood vessels and, hence, low oxygen 
concentrations. It is interesting to note that since the 
small GTPase Rac-1 is a well-known activator of p66-
induced oxidative stress [25], it also plays an essential 
part in the maintenance and self-renewal of epider-
mal stem cells. Taken together, these data show that 
p66shc has a more complex role, acting as a “double-
edged sword” in the regulation of apoptosis, based on 
environmental conditions and genetic context.
MECHANISMS OF P66-DEPENDENT 
INCREASE IN CELLULAR ROS LEVELS
By now, we know the mechanisms p66shc exploits to 
increase intracellular ROS levels: activation of mem-
brane-bound NADPH-oxidases, down-regulation of 
antioxidant enzymes synthesis, and generation of ROS 
in mitochondria.
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Fig. 1. Schematic presentation of domain structure of 
SHC-like proteins. Modified amino acid residues denoted 
as: serine 36 and 54 (S36 and S54), cysteine 59 (C59), 
threonine 386 (T386) and tyrosines (Y) phosphorylated 
during signal transduction from tyrosine kinase receptors.46 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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p66-dependent Activation of Membrane-bound 
NADPH-oxidases
First of all, it should be noted that p66shc can cause 
oxidative stress in the cell carrying out its primary 
function of adaptor protein. As was mentioned above, 
this protein can negatively regulate RAS-activation by 
means of displacing the nucleotide exchange factor SOS 
from its complex with GRb2. It has turned out that this 
chain of events can be accompanied by the SOS-de-
pendent activation of small GTPase Rac-1, which con-
sequently promotes the assembly of membrane-bound 
NADPH-oxidases and the production of ROS [12] (Fig. 
2). It has been shown that p66shc is necessary for apop-
tosis induced by a constitutively active Rac-1 mutant. 
However, this apoptosis scenario does not involve the 
phosphorylation of Ser36 but phosphorylation of Ser54 
and Thr386, instead, which promotes Rac-1-dependent 
Table 1. Cellular models of p66shc inactivation (via either p66shc gene deletion or expression of а dominant-negative 
mutant of p66shc at S36) with phenotype of apoptosis resistance
Cells Cell line name Organism Apoptosis inducer References
Embryonic fibroblasts MEF mouse H2O2, UV, staurosporine, 
isothiocyanate, chloroform [2, 15, 17, 18]
Primary cardiomyocyte mouse angiotensin II [19]
Transformed renal epithelial cells TKPTS mouse H2O2, cisplatin [13]
Hepatocytes transgenic for human 
TGFa AML12 mouse hypoxia-reoxygenation [20]
Endothelial progenitor cells BM c-kit+ mouse high glucose in media [21]
Osteoblastic cells OB-6, UAMS-32  mouse H2O2 [22]
Pheochromocytoma PC12 rat beta amyloid, constitutively 
active Rac1 mutant  [23]
Cardiomyocyte  ARVM rat high glucose in media [24]
Transformed fibroblast-like cells COS7 green monkey constitutively active Rac1 
mutant [25]
Neuroblastoma SH-SY5Y human beta amyloid [23]
Human podocytes immortalized with 
SV40-T-antigen CIDHPs human HIV-1 transfection [26]
Prostatic carcinoma PC3, LNCaP human isothiocyanate [18]
Cervical carcinoma HeLa human H2O2 [27]
Osteosarcoma SaOs-2 human H2O2 [27]
Retinal pigmented epithelial
Cells RPE human H2O2 [28]
Lymphoma Jurcat human hypoxia, calcium ionophores [29]
Transformed renal epithelial cells φNx-293 human cell detachment from a solid 
matrix [30]
Endothelial cells HuVec human cell detachment from a solid 
matrix [30]
Table 2. p66 involvement in the development of patholo-
gies associated with oxidative stress and demonstrated 
on physiological models (experiments with p66shc knock-
out animals or comparison between young and elderly 
individuals) 
Pathology associated with 
apoptosis
Organism 
and genetic 
line 
Reference
Experimental diabetic 
glomerulopathy
mouse, 
SV/129 [5]
Vascular cell apoptosis and 
atherogenesis  
induced by high-fat diet 
mouse, 
SV/129 [3]
Cardiomyocyte apoptosis in 
experimental model  of diabe-
tes induced by streptozotocin
mouse, 
SV/129 [31]
Cerebral cortex hypoxia rat, Sprague–
Dawley  [32]REVIEWS
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stabilization of p66shc and protects against ubiquitin-
mediated degradation [25]. In macrophages, where 
NADPH-oxidase serves as the major source of ROS, 
knockout of the p66shc gene undermines the forma-
tion of the active NADPH-oxidase complex, ultimately 
leading to a 40% decrease in ROS-formation. 
p66shc and Regulation of Expression of Antioxidant 
Enzymes
Previous research has shown that p66shc reduces the 
expression of such antioxidant enzymes and regula-
tory factors as glutathione peroxidase-1 [28], MnSOD 
[7, 20, 28], and REF-1 [20] by means of down-regulation 
of Forkhead-type transcription factors (e.g., Foxo3a) 
[23, 40, 41]. In the course of oxidative stress, serine/
threonine protein kinase Akt undergoes phosphoryla-
tion and in turn phosphorylates and inactivates Foxo3a. 
This reaction requires the presence of p66shc in the cell 
[40] and also its phosphorylation at Ser36 [42]. Outside 
of that, some data suggest that p66shc, in complex 
with βPix (a nucleotide exchange factor for Rac-1 and 
Cdc42), can cause Akt-independent phosphorylation 
and the inactivation of Foxo3a [43] (Fig. 3).
It should be mentioned that these data are in disa-
greement with a number of publications which argue 
that p66shc does not affect the levels of antioxidant en-
zymes [4, 15-17].
p66shc and Mitochondria-mediated Apoptosis
The fact that cells carrying deletion of the p66shc gene 
are resistant to various inductors of mitochondria-me-
diated apoptosis implies a direct interaction between 
p66 and mitochondria. 
Mitochondrial localization of p66shc and its transport 
to mitochondria. Studies on the cellular localization of 
p66shc showed that 32% of this protein is localized in 
the cytoplasm; 24% is in the endoplasmic reticulum; 
and 44%, in mitochondria [17]. Inside the mitochondria, 
p66shc is distributed in the following manner: 35% is in 
the intramembrane space, 56% is associated with the 
inner membrane, and 9% is located in the mitochondrial 
matrix [15]. According to other data, mitochondria con-
tain only 10% of cellular p66shc [44]. These differences 
told arise from the changes in p66shc intracellular lo-
calization caused by external influences. 
The stimuli that promote p66shc translocation into 
mitochondria are usually pro-apoptotic factors, such 
as UV radiation and treatment with H2O2 [17, 35]. How-
ever, the mechanism of p66shc transport into mito-
chondria remains unknown. It is known that a short 
Shc isoform p46shc is also localized in mitochondria 
and contains the signal of mitochondrial import [45]. 
However, mutations in a similar mitochondrial import 
sequence in p66 did not affect its localization - which 
probably means that this signal is somehow masked 
by the N-terminal CH2-domain [44]. It was also shown 
that p66shc is associated with protein complexes that 
contain mHSP70, TIM, and TOM subunits and mediate 
protein transport into mitochondria. P66 is thought to 
be inactive in these complexes; however, it is believed 
that under oxidative stress p66 dissociates and thus ac-
quires active conformation [46].
According to data presented in [35], the signal path-
way that initiates p66shc translocation into mitochon-
dria upon H2O2 treatment includes the activation of 
PKCβ, which phosphorylates p66 at Ser36. Phosphor-
ylated p66 becomes a target of prolylpolymerase Pin-1 
that recognizes a proline residue, which follows phos-
phorylated serine. After isomerization, p66shc is de-
phosphorylated by PP2A phosphatase and transported 
into mitochondria. The latter event is confirmed by the 
GRb2
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Fig. 2. P66-dependent activation of plasma membrane 
NADPH oxidases. P66shc displaces nucleotide exchange 
factor SOS from Grb2 complex and promotes activation 
of small GTPase Rac1. Activated Rac1 stimulates NADPH 
oxidase complex formation and ROS generation.
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Fig. 3. P66 role in regulation of the cellular antioxidant 
defense system. P66 can downregulate antioxidative fer-
ments and regulatory factors. This downregulation can be 
induced through both Akt-dependent and Akt-independ-
ent inactivation of Forkhead transcription factors.48 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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fact that the pool of mitochondrial p66shc is not phos-
phorylated [15] (Fig.4). It was also shown in [35] that the 
absence of p66shc also results in altered Ca-signaling 
and prevents the fragmentation of mitochondria, which 
is related to resistance to apoptosis. 
Redox proapoptotic activity of p66shc and the produc-
tion of ROS. Current views hold that, in the course of 
mitochondrial-dependent apoptosis, various signals 
(ROS, elevated Ca, uncoupled oxidative phosphoryla-
tion) promote the formation of a multi-subunit protein 
complex, which eventually forms a pore in the inner 
mitochondrial membrane. The permeabilization of both 
mitochondrial membranes results in the release of Cyt 
C and other proteins in the cytoplasm, apoptosome for-
mation, and caspase activation [47].
Pelicci et al. have suggested a mechanism explain-
ing the role of p66shc in mitochondrium-dependent 
apoptosis [15]. It turns out that p66shc is necessary for 
a drop in the membrane’s potential and Cyt C release 
in cytosol. Moreover, the addition of cyclosporine A, 
an inhibitor of permeability transition pore formation, 
blocked the pro-apoptotic function of p66shc [17]. In 
vitro showed that the addition of recombinant p66shc 
to isolated mitochondria with a permeabilized outer 
membrane results in mitochondria swelling as a result 
of permeability transition pore formation. This effect 
was also inhibited by cyclosporine A, catalase, antioxi-
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Fig. 4. Model for induction proapoptotic signaling in mitochondria. p66shc (denoted as orange circle) can exist as dimer 
(circles where “SH” indicates reduced cysteine residue 59) and tetramer (circles with “S” indicating an oxidized cysteine 
residue 59). Circles with “S?” indicating unknown redox state of a cysteine residue 59 that is responsible for tetram-
erisation p66. Interaction of p66shc with peroxiredoxin 1 (Prx1, denoted as violet oval) in cytosol results in a complex 
presumably consisting of dimeric p66 and dimeric Prx1 in which Prx1 peroxidase activity degrades p66-generated ROS. 
Oxidative stress leads to dissociation of the complex; PKCβ phosphorylates released p66 on S36. Phosphorylated p66 
becomes a target for prolyl isomerase Pin1, which recognizes proline following phosphorylated serine residue. After 
izomerization PP2A dephosphorylates p66shc, which is then transported into mitochondria. During oxidative stress 
p66shc is released from the high-molecular-mass complex that contains TOM, TIM, and mHsp70. Released p66shc acts 
as oxidoreductase and transfers electrons from reduced Cyt C to oxygen. As a result, generated ROS lead to perme-
ability-transition pore (PTP) opening and induction of apoptosis. These consequences may appear after tetrameric p66 
formation during oxidative stress and following depletion of the thoredoxin and glutathione pool (for full explanation, see 
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PTP – permeability transition pore; TMPD – N,N,N’,N’- tetramethyl-p-phenyldiamine; TRX – thioredoxin.REVIEWS
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dant dimethylthiourea, and the inhibitor of complex 
III of the respiratory chain antimycin A, as well as be-
ing dependent on respiratory substrates. Therefore, the 
obtained data is evidence that permeability-transition 
pore formation is a key step in p66-mediated apoptosis 
and that ROS and respiration are also necessary in this 
process. 
The application of electrochemical analysis and fluo-
rescent redox-sensitive probes revealed that p66 acts as 
a redox enzyme and transfers electrons from reduced 
Cyt C to oxygen. The interaction of p66 with Cyt C is 
mediated by the CB-domain, which was confirmed by 
ELISA and site-directed mutagenesis [17]. Incomplete 
oxygen reduction leads to ROS production, which in 
turn promotes the formation of a permeability-transi-
tion pore. In confirmation of this hypothesis, ROS for-
mation was shown upon the addition of p66 to mito-
chondria in the absence of substrates of respiration in a 
medium supplemented with ascorbate/TMPD.,  a redox 
couple that selectively reduces Cyt C. ROS formation 
was also observed even in the absence of mitochondria 
upon mixing of Cyt C and p66shc. However, in this case, 
the presence of copper ions was indispensable. 
Therefore, the Pelicci group suggested the following 
mechanism of pro-apoptotic action of p66shc (Fig. 4): 
under normal conditions, p66shc is inactivated and rep-
resents a part of the multi-subunit complex compris-
ing TIM, TOM, and mHSP70. Oxidative stress causes 
p66shc to dissociate from the complex. As a result, 
p66shc acts as a redox enzyme and transfers electrons 
from the reduced Cyt C to oxygen. The incomplete re-
duction of oxygen results in ROS production, which 
promotes the formation of a permeability-transition 
pore, mitochondrial swelling, Cyt C release to cytosol, 
apoptosome assembly, and caspase activation.
It is important to realize that the suggested mech-
anism of p66shc redox activity, which includes Cyt C 
as an electron donor, is only a reality in vitro. In order 
to validate this hypothesis, one needs to carry out ad-
ditional experiments based on fluorescent probes for 
measuring ROS levels in the mitochondria of cells with 
an inactive respiratory chain (Rho-0 cells), as well as in   
cells devoid of Cyt C.
It should be noted that the described model has 
many weak points. For example, p66shc does not con-
tain any well-known redox domains or metal-binding 
domains. Therefore, its ability to generate ROS only 
in the presence of copper ions can be an artifact, since 
copper ions are known to be able to generate ROS dur-
ing Fenton’s reaction, which could affect the results ob-
tained by means of redox-sensitive fluorescent probes. 
It is also known that Cyt C, upon oligomerization, can 
produce ROS as a result of auto-oxidation [48-52]. Tak-
ing this into account, one can suggest that p66shc, upon 
binding with Cyt C, can act as a factor promoting oli-
gomerization and the auto-oxidation of Cyt C, similarly 
to ptothymosine α, but not as a redox enzyme [53].
Studies on an isolated CH2-CB-domain. The mecha-
nism of action of p66shc was also studied in  in vitro 
experiments with an isolated CH2-CB-domain. It 
turns out that the recombinant CH2-CB-domain can 
exist in two forms: reduced, as a dimer, and oxidized, 
as a tetramer (or a dimer of dimers) which contains 
disulfide bridges between residues Cys59. The addi-
tion of both the CH2-CB-domain and the full-length 
protein to mitochondria resulted in the formation of a 
permeability transition pore and swelling; however, 
only the tetramer exhibited such a pro-apoptotic ac-
tivity. In contradiction to the data presented in [15], 
which suggested that ROS production is directly con-
nected to permeability-transition pore formation, the 
tetramer form of the recombinant CH2-CB-domain 
generated less ROS than the dimer when mixed with 
isolated mitochondria.
Apart from that, the CH2-CB-domain was shown to 
trigger ROS production in the presence of dithionite (as 
an electron donor) and copper ions. However, this ef-
fect was not reproduced when dithionite was replaced 
with Cyt C as an electron donor. Apparently, the other 
domains of p66shc are necessary either for interaction 
with Cyt C or for maintenance of the CH2-CB-domain 
in proper conformation.
As a result of the above-described findings, a refined 
model of p66-mediated apoptosis was suggested. The 
model assumes that under normal conditions the tetra-
meric form of p66 is reduced by mitochondrial antioxi-
dant systems. Under stress conditions, however, anti-
oxidant systems are not able to retain p66shc in their 
reduced dimeric state, so the oxidized tetrameric forms 
generate ROS locally, which triggers permeability-
transition pore formation and apoptosis. 
It is important to note that a direct connection be-
tween the ROS-generating and pro-apoptotic functions 
of p66shc does not necessarily exist. For example, a con-
firmation of this fact can be the lower level of ROS pro-
duction in the case of pro-apoptotic tetrameric forms 
of p66shc in comparison to the dimer, which does not 
induce apoptosis.
p66 as a redox sensor. Extensive experiments on the 
isolated CH2-CB-domain revealed a new interaction 
partner of p66shc – peroxiredoxine 1 (Prx1). Prx1 is 
a member of the peroxidase family. These enzymes 
regulate the redox balance in the cell. Prx1 can exist 
in the form of a dimer, a decamer (5 dimers) or a mul-
timer. Prx1 is basically localized in cytosol, though re-
cent proteomic studies have revealed its presence in 50 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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the perimitochondrial compartment. Under normal 
conditions, Prx1 exists predominantly in dimeric form, 
which functions as peroxidase. When the cell is under 
stress, Prx1 undergoes oxidation and forms decamers 
that possess lower peroxidase activity. However, upon 
these transformations Prx1 acquires a chaperone func-
tion. Severe oxidative stress leads to the formation of 
the multimer, which is also devoid of peroxidase activ-
ity but can function as a chaperone [56-58].
Interactions between the CH2-CB-domain of p66shc 
and Prx1 result in the destabilization of the decameric 
form of Prx1 and favor dimeric form transition. In turn, 
Prx1, in complex with p66shc, retains p66shc in dimer-
ic form by means of a disulfide exchange between the 
two proteins. The resulting hybrid complex consists 
of dimeric p66shc, which generates ROS but has low 
pro-apoptotic activity, and dimeric Prx1, which func-
tions as a peroxidase. Thus, under normal conditions 
dimeric Prx1 stabilizes the inactive state of p66shc and 
degrades ROS which are produced by p66shc. Under 
stress conditions, cystein residues of proteins are oxi-
dized, resulting in disassembly of the complex: so, the 
uncomplexed p66shc can now participate in apopto-
sis induction [55]. Therefore, the complex of dimeric 
p66shc and dimeric Prx1 can be considered as a sensor 
that detects the level of cellular ROS and induced ap-
optosis when excessive amounts of ROS are accumu-
lated (Fig. 4).
CONCLUSION
According to current views, p66shc is a pro-apoptotic 
protein which regulates oxidative stress and induces the 
mitochondrial apoptosis pathway by means of redox ac-
tivity. Although the physiological role of p66shc has been 
extensively studied, little is known about the precise 
mechanism of action underlying its redox functions and 
participation in apoptosis induction. Further studies will 
endeavor to elucidate the precise mechanism of p66shc 
translocation into mitochondria and the localization of 
p66shc-dependent ROS production in the cell. Although 
p66shc phosphorylation at Ser36 is one of the indispen-
sible steps of apoptosis, it was shown that the mitochon-
drial pool of p66 is not phosphorylated. This indicates that 
p66shc phosphorylated at Ser36 probably participates in 
pro-apoptotic events outside mitochondria. 
P66shc is undoubtedly interesting in terms of the in-
vestigation of oxidative stress, apoptosis, and the aging 
related to it. It is important to note that, to estimate the 
involvement of p66shc in age-related disorders, it is nec-
essary to better understand its role in cancer. A deeper 
understanding of the regulatory pathways and structur-
al and mechanistic bases of p66shc redox activity can be 
important for developing pharmacological approaches to 
the treatment of age-related disorders. 
The author is grateful for the valuable comments and 
help provided in the preparation of the manuscript by 
B.V. Chernyak and V.P. Skulachev. 
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